Tirzepatide slows gastric emptying. Anything swallowed alongside it therefore leaves the stomach later, and a drug that depends on being absorbed quickly can behave differently as a result. Oral contraception is the case where that matters most, and it is the case where the published data is thinnest.
The one pharmacokinetic study, and its actual numbers
A single 5 mg dose of tirzepatide given with a combined oral contraceptive reduced the peak plasma concentration of ethinylestradiol by 59%, of norgestimate by 66% and of its active metabolite norelgestromin by 55% [1]. Total exposure fell by much less: 20%, 21% and 23% respectively. Time to peak was delayed by 2.5 to 4.5 hours.
Those two sets of figures are the whole of this question. A 59% fall in peak concentration sounds alarming and a 20% fall in exposure does not, and they describe the same event. The review reporting them makes the point directly: a fall in peak concentration cannot be equated with reduced efficacy. Contraceptive effect depends far more on exposure across the day than on how high the curve gets in hour two. Whether a 20% reduction in exposure is enough to matter has not been measured in a clinical outcome study, and the honest answer to the question is that nobody has tested it. That is the same shape as the gap the sexual function evidence has, for the same reason: the trials were designed to measure weight.
Why the risk is concentrated at the start
The slowing of gastric emptying is greatest after a first dose and diminishes with continued treatment [1]. Any interaction is therefore concentrated during initiation and during each dose escalation, rather than spread evenly across a course of treatment. This is the practical consequence of the finding, and it is why the labeling advice is framed around the four weeks after starting and after every increase rather than around the whole prescription.
That timing matters commercially as well as clinically. A seller whose price rises at each dose step is a seller whose escalation schedule a reader has a financial reason to compress, and the escalation is the window this interaction lives in. The titration evidence covers the same window from the tolerability side.
What this does and does not extend to
The study used one combined oral contraceptive formulation. A pharmacokinetic review of the approved GLP-1 and dual agonists notes that interaction findings are formulation-specific and are not automatically transferable between structurally different agents[2]. No equivalent data exists for progestogens prescribed for gynecologic indications or for endometrial protection during menopausal hormone therapy[1]. A reader taking one of those is in a position the published record does not cover, which is a different statement from being at no risk.
Semaglutide is a separate question with a separate answer, and this page does not extend the tirzepatide finding to it. The two molecules slow gastric emptying to different degrees and have been studied separately.
The label is the document that governs
The prescribing information for tirzepatide carries the contraception advice that a prescriber acts on, and it is the primary source here rather than any review of it[3]. A review can describe a study; only the label sets out what the manufacturer and the FDA agreed the advice should be. Read it before deciding anything on the strength of a percentage.
What to ask a prescriber
The question worth asking is not whether the interaction exists but what to do during the four weeks after starting and after each increase. A service that makes a clinician reachable in that window is worth more here than one that is cheaper by $20 a month, and what each seller publishes about clinician access is recorded in the seller reviews and applied by the editorial methodology.